Drug Trial Radar · NCT02394483
Single Ascending Oral Dose Study of F901318
Last checked: Nov 19, 2026Latest source record: Sep 19, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Oct 2015
Primary completion
Sep 2016
Study completion Sep 2016
Sponsor
- Lead sponsor
- F2G LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Simbec-Orion Group
- First posted
- Mar 20, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Double blind, placebo controlled, ascending single oral dose, sequential group study. Forty subjects will complete the study in 5 cohorts (Groups A to E), each group consisting of 8 subjects. Each subject will be on study for approximately 6 weeks. Each subject will participate in one treatment cohort only, residing at the Clinical Research Unit (CRU) from Day -1 (the day before dosing) to Day 6 (120 hours post-dose). Each cohort will be dosed in a leading edge design in which two subjects will receive study drug (1 active and 1 placebo) on the first dosing day, and the last 6 will receive study drug (5 active and 1 placebo) on the second dosing day. All subjects will return for a post-study visit 8 to 10 days after the dose of study medication. Cohorts will be dosed at 2 weekly intervals. There will be a review of safety data, after the first two subjects have been dosed and before dosing of the subsequent six subjects. There will be a complete review of safety and pharmacokinetic data of each cohort prior to each dose escalation.
Conditions
- Invasive Aspergillosis
Interventions
F901318 safetyDrug
Safety assessments
F901318 tolerabilityDrug
Tolerability assessments
F901318 pharmacokineticsDrug
Pharmacokinetic assessments
Placebo safetyOther
Safety assessments
Placebo tolerabilityOther
Placebo tolerability
Placebo pharmacokineticsOther
Plaacebo pharmacokinetics
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety (Adverse events)Time frame: 10 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Simbec Orion
Merthyr Tydfil, Wales, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.